title: Predictive and prognostic factors in small cell lung carcinoma (SCLC)--analysis from routine clinical practice.
abstract: BACKGROUND
  Prognostic and predictive factors of routine clinical practice among patients with small cell lung carcinoma (SCLC) were evaluated.
  
  
  METHODS
  Data from 106 patients with SCLC treated by first-line adriamycin, cyclophosphamide and etoposide (ACE) chemotherapy were analyzed. Multivariate analysis was performed.
  
  
  RESULTS
  The median overall survival (mOS) of patients was 9.36 months with mOS of 31%, 8% and 3% after 1, 2 and 5 years, respectively. Using multivariate analysis ECOG performance status (p =0.008) and white blood count (WBC) (p=0.022) were independent prognostic factors for mOS. With both, three groups of outcome (good, intermediate, poor) resulting in mOS of 15.8 months, 6.87 months and 3.35 months (p<0.0001) could be established, respectively. The absence of brain metastases (p=0.002), dose reduction (p=0.002) and LDH value (p=0.017) were independent predictive markers. Additionally, female gender was predictive (p=0.025) for complete response (CR).
  
  
  CONCLUSIONS
  Patients with a poor prediction profil might not benefit from ACE chemotherapy. As a consequence, prognostic/predictive factors should be included as stratification criteria in prospective clinical studies.
authors.affiliation: Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany. wolfgang.brueckl@med1.imed.unierlangen.de
authors.forename: Wolfgang M
authors.initials: WM
authors.lastname: Brueckl
authors.forename: Lara
authors.initials: L
authors.lastname: Herbst
authors.forename: Annette
authors.initials: A
authors.lastname: Lechler
authors.forename: Florian
authors.initials: F
authors.lastname: Fuchs
authors.forename: Anja
authors.initials: A
authors.lastname: Schoeberl
authors.forename: Sabine
authors.initials: S
authors.lastname: Zirlik
authors.forename: Peter
authors.initials: P
authors.lastname: Klein
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Brunner
authors.forename: Thomas
authors.initials: T
authors.lastname: Papadopoulos
authors.forename: Werner
authors.initials: W
authors.lastname: Hohenberger
authors.forename: Eckhart G
authors.initials: EG
authors.lastname: Hahn
authors.forename: Gunther H
authors.initials: GH
authors.lastname: Wiest
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide